Tumor blood volume: a prognostic biomarker for anaplastic astrocytomas?
نویسندگان
چکیده
منابع مشابه
Anaplastic Astrocytomas and Oligodendrogliomas
The recommendations contained in this guideline are a consensus of the Alberta Provincial CNS Tumour Team synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.
متن کاملOverexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas
The epidermal growth factor receptor (EGFR) family, consisting of four tyrosine kinase receptors, c-erbB1-4, seems to be influential in gliomagenesis. The aim of this study was to investigate EGFR gene amplification and expression of c-erbB1-4 receptor proteins in human anaplastic astrocytomas. Formalin-fixed and paraffin-embedded sections from 31 cases were investigated by standard immunohisto...
متن کامل[The heterogeneity of blood flow on magnetic resonance imaging: a biomarker for grading cerebral astrocytomas].
OBJECTIVES To study whether the histograms of quantitative parameters of perfusion in MRI obtained from tumor volume and peritumor volume make it possible to grade astrocytomas in vivo. MATERIAL AND METHODS We included 61 patients with histological diagnoses of grade II, III, or IV astrocytomas who underwent T2*-weighted perfusion MRI after intravenous contrast agent injection. We manually se...
متن کاملAnaplastic Astrocytomas: A Review of Biology and Treatment
Anaplastic astrocytomas (AA), World Heath Organization (WHO) grade III gliomas, comprise 10-15% of all glial neoplasms. Currently the only factors that have been shown to influence prognosis in patients with AA are the age and Karnofsky performance status (KPS). Attempts have been made to identify biological prognostic factors for response to therapy and clinical outcome as well as potential ta...
متن کاملSalvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas.
BACKGROUND A prospective phase 2 study of daily oral tamoxifen citrate in young adults with recurrent anaplastic astrocytomas. METHODS Twenty-four patients (15 men; 9 women) aged 19 to 45 years (median age, 31.5 years) with recurrent anaplastic astrocytomas were treated. All patients had been treated previously with surgery and involved-field radiotherapy (median dose, 60 Gy; range, 59-61 Gy)...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: CNS Oncology
سال: 2014
ISSN: 2045-0907,2045-0915
DOI: 10.2217/cns.14.5